TFA
CORT icon

Transamerica Financial Advisors’s Corcept Therapeutics CORT Stock Holding History

Transamerica Financial Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Buy
1,789
+758
+74% +$45.8K 0.01% 474
2026
Q1 		$41.6K Buy
1,031
+557
+118% +$20.8K ﹤0.01% 674
2025
Q4 		$16.5K Buy
474
+296
+166% +$23.2K ﹤0.01% 754
2025
Q3 		$14.8K Buy
+178
New +$12.9K ﹤0.01% 658

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Transamerica Financial Advisors's CORT Position: Q2 2026 in Review

Transamerica Financial Advisors increased its Corcept Therapeutics (CORT) stake by 74% in Q2 2026, buying an estimated $45.8K and bringing the position to 1,789 shares worth $156K. The position accounts for 0.01% of the portfolio, ranked #474.

Transamerica Financial Advisors first reported a position in CORT in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Transamerica Financial Advisors held 1,789 shares of Corcept Therapeutics worth $156K as of Q2 2026.
  • Transamerica Financial Advisors bought 758 Corcept Therapeutics shares in Q2 2026, an estimated $45.8K.
  • Corcept Therapeutics made up 0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #474 holding.
  • Transamerica Financial Advisors first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.